Moreover, CUR administration efficiently blocks the phosphorylation of the inhibitor of kappa B (IKK) and the inhibitor of NF-κB (IκB), which are necessary for the translocation of NF-κB into the nucleus in ulcerative colitis and cancer cells (54, 55). This evidence concerns the gene NFKB1 and cancer.